MRK

With the lagging performance aside, there have been some notable big winners among the index's 30 components. Read more here.

SeekingAlpha · 1d ago

Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.

Yahoo · 1d ago

Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.

ChartMill · 1d ago

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Yahoo · 2d ago

Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...

Yahoo · 2d ago

Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.

Yahoo · 2d ago

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

Yahoo · 2d ago